Companies researching Imbruvica (ibrutinib)
Imbruvica (ibrutinib) is a small‑molecule BTK inhibitor that blocks B‑cell receptor signaling, used to treat B‑cell malignancies such as chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion and Waldenström’s macroglobulinemia.
12
companies
List of companies that research Imbruvica (ibrutinib)
This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →
Employees60kRevenue$26BPharmaceutical ManufacturingImbruvica (ibrutinib)High confidence
Employees138kRevenue$94BHospitals and Health CareImbruvica (ibrutinib)Low confidence
Employees5kHospitals and Health CareImbruvica (ibrutinib)Low confidence
Employees452Revenue$23MMedical PracticesImbruvica (ibrutinib)Low confidence
Employees25kRevenue$5.9MHospitals and Health CareImbruvica (ibrutinib)Low confidence
Employees4.2kRevenue$500MHospitals and Health CareImbruvica (ibrutinib)Low confidence
Showing top companies out of 12 that research Imbruvica (ibrutinib). Get the full list on TheirStack.
Frequently asked questions